Open access
Real-World Effectiveness of Maternal RSVpreF Vaccination and Durability of Infant Protection
Han-Meng Xu
C. Aparicio-Llorente
A. Wats
B. L. Araujo
J. Ganem
I. O. Oliva
E. D. Shapiro
N. Brodsky
P. Aronson
N. Grubaugh
Carrie L. Lucas
L. Niccolai
J. L. Warren
L. Kennedy-Shaffer
V. Pitzer
D. M. Weinberger
C. R. Oliveira
Medicine
Abstract
In this test-negative study, the effectiveness of the maternal RSVpreF vaccine among infants <6 months was 73.9% against medically attended respiratory syncytial virus (RSV) infection and 86.3% against RSV-associated hospitalization. Maternal RSVpreF and nirsevimab had comparable initial effectiveness, but effectiveness of RSVpreF waned approximately 1.7 times more rapidly.